21 news items
Sage Therapeutics to Participate in Upcoming May Investor Conferences
SAGE
7 May 24
treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
SAGE
1 May 24
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $25
SAGE
26 Apr 24
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $28 to $25.
Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $18
SAGE
26 Apr 24
Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $20 to $18.
Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17
SAGE
26 Apr 24
Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $21 to $17.
tfa9ul3dqwjngtagf6vjvdv2z9490pz5 0qv1ib
SAGE
25 Apr 24
featuring internally discovered novel chemical entities with the potential to become differentiated products designed to improve brain health by targeting
l1i0wxieq9lk2yxiq7ufa2or
SAGE
18 Apr 24
Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Outperform and lowers the price target from $34 to $19.
ai3ui32z
SAGE
18 Apr 24
Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Perform and lowers the price target from $25 to $17.
uro5prp3fq
SAGE
18 Apr 24
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.67
awlh0cxpx0noioysppkog0qpz7jsdp5
SAGE
18 Apr 24
TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $30 to $16.
1pc04wyus94l2uljhal07y8y vxv7v
ADPT
ADSK
ALXO
17 Apr 24
analyst Hartaj Singh maintained Viracta Therapeutics with an Outperform and maintained a $13 price target.
Spectaire Holdings Inc
s1d8nm6wnjq436svgw48rzmg5jc4mqu6nrzy2966ye385v2qgwrb
SAGE
17 Apr 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $28 price target.
l4cjjwfejvcs4gab8 y5
SAGE
17 Apr 24
Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $24 price target.
gtqlkr
SAGE
17 Apr 24
(NASDAQ:SAGE) from Neutral to Underperform and lowers the price target from $24 to $14.
8c51235 1wcs32elxhuahxs948pmd5npwvk9876
SAGE
17 Apr 24
and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out
5zqkf25asll1u brc8f0afgc17rtqc0auv6bsu0i1dxvp6j5noor017jm0
SAGE
11 Apr 24
depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find
9l3fqd9
SAGE
26 Mar 24
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.2
42l pwtnvd6kl4lyxtqg
SAGE
11 Mar 24
RBC Capital analyst Brian Abrahams reiterates Sage Therapeutics (NASDAQ:SAGE) with a Sector Perform and maintains $26 price target.
xv2adh8avz8z
SAGE
28 Feb 24
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target
7a45ujdzwf78hetkyr8ii63o6t0cf1dvoc gyav8h87hod5qy4x2spxl0
SAGE
28 Feb 24
Morgan Stanley analyst Vikram Purohit maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and raises the price target from $20 to $22.